Retatrutide 5/10/15/30 mg

What is Retatrutide?

Retatrutide (CAS 2381089-83-2) is a new-generation synthetic peptide analogue, described in the clinical and pharmacological literature as a triple agonist — a single molecule that simultaneously activates three receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and GCGR (the glucagon receptor). This triple action sets retatrutide apart from incretin peptides that act on one or two receptors and is the basis of the scientific interest in the molecule in the fields of metabolism and GLP-1, GIP and glucagon receptor signalling.

Unlike the single agonist Semaglutide (GLP-1 only) and the dual agonist Tirzepatide (GLP-1 + GIP), retatrutide adds glucagon activity. It is precisely the glucagon component that is linked in the published literature with activation of the glucagon receptor (GCGR) — beyond activation of the GLP-1 and GIP receptors.

Retatrutide is being studied in several therapeutic areas: obesity (Phase II, published in the New England Journal of Medicine, 2023), type 2 diabetes (Phase II, The Lancet, 2023), metabolic dysfunction-associated steatotic liver disease (MASLD/NASH, Phase IIa, Nature Medicine, 2024), as well as in the ongoing, large-scale Phase III TRIUMPH programme. At present retatrutide is an experimental drug candidate — it is not approved by the FDA or the EMA for clinical use. See also the other peptides for weight loss — GLP-1 agonists in our category.

In the Peptology version, retatrutide is supplied as a lyophilised research peptide with purity above 99%, confirmed by independent laboratory analysis (CoA) for each batch. It is available in four vial sizes — 5 mg, 10 mg, 15 mg and 30 mg, depending on the scale of the research protocol. It is NOT an approved medicinal product — the product is intended exclusively for scientific, research and in vitro applications.

How retatrutide works — triple receptor agonist action

In clinical and preclinical publications, retatrutide is described as a molecule with three simultaneous receptor actions. These three mechanisms work in a coordinated way and are described in the literature as simultaneous signalling at the GLP-1, GIP and glucagon receptors — a combination that is not achieved with incretin peptides that act on one or two receptors.

Why the glucagon component matters

Most incretin peptides act only on the GLP-1 receptor (such as Semaglutide) or on the GLP-1 and GIP receptors (such as Tirzepatide). The addition of controlled glucagon activity is a fundamentally different approach — in the literature, glucagon receptor agonist action is described at the level of the receptor (GCGR) and intracellular signalling (cAMP). This makes retatrutide a subject of particular scientific interest in models of metabolic dysfunction-associated steatotic liver disease (MASLD/NASH).

This idea was explored in a Phase IIa study in MASLD, published in Nature Medicine (2024), in which retatrutide was associated with a significant reduction in liver fat content compared with placebo. These results come from controlled clinical trials and are not a guarantee of an individual result, nor a claim about the action of a research-grade product.

Pharmacokinetics and pharmacodynamics of retatrutide

Retatrutide is a peptide with a relatively long half-life; published pharmacokinetic studies describe it as a molecule with predictable, linear kinetics.

• Half-life (literature): approximately 6 days
• Structure: 39-amino-acid peptide with a fatty chain that binds to albumin
• Molecular formula / molecular weight: C221H342N46O68 · ≈4731 g/mol
• CAS number: 2381089-83-2
• Kinetics: linear in the range studied

Retatrutide vs. Tirzepatide vs. Semaglutide

The table below compares retatrutide with the two most frequently studied incretin peptides in the catalogue. All three molecules are studied for metabolic regulation and body weight control, but they act on a different number of receptors — Semaglutide on one (GLP-1), Tirzepatide on two (GLP-1 + GIP) and retatrutide on three (GLP-1 + GIP + glucagon). The data are presented as scientific reference and do not constitute a direct head-to-head comparison.

Sources: Jastreboff et al., NEJM (2023) for retatrutide in obesity; Rosenstock et al., The Lancet (2023) in type 2 diabetes; Sanyal et al., Nature Medicine (2024) in MASLD; the SURMOUNT (Tirzepatide) and STEP (Semaglutide) programmes. The data presented come from different clinical programmes and should not be interpreted as a direct comparison, nor as a claim about the result of a specific research-grade product.

Clinical studies of retatrutide

The clinical programme of retatrutide is developing in several parallel directions — obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD/NASH) and the ongoing, large-scale Phase III TRIUMPH programme. The Phase II results are among the strongest reported in the incretin category, but the molecule has not yet received regulatory approval.

Phase I — safety and pharmacokinetics

In early clinical studies in healthy volunteers and in patients with type 2 diabetes, predictable, dose-proportional pharmacokinetics were documented, together with a long half-life (~6 days), compatible with weekly administration, and an adverse-event profile dominated by dose-dependent gastrointestinal effects — characteristic of the incretin class.

Phase II — obesity (NEJM, 2023)

The study, published in the New England Journal of Medicine (Jastreboff et al., 2023), included 338 adults with obesity without type 2 diabetes, who were randomised to retatrutide 1, 4, 8 or 12 mg SC weekly or to placebo for 48 weeks. At the highest dose (12 mg), the mean reduction in body weight reached ~24.2%, while the threshold of a reduction of ≥ 5% was achieved by all participants at 8 mg and 12 mg. Improvements were also observed in cardiometabolic markers — waist circumference, blood pressure, HbA1c, fasting glucose, insulin and lipid profile. These results come from a controlled clinical trial and are not a recommendation for individual use.

Phase II — type 2 diabetes (The Lancet, 2023)

In a randomised Phase II study in patients with type 2 diabetes (Rosenstock et al., 2023), retatrutide was associated with dose-dependent reductions in HbA1c and body weight compared with placebo and with an active comparator. The data supported the dual metabolic hypothesis — simultaneous glycaemic control and weight reduction.

Phase IIa — MASLD / NASH (Nature Medicine, 2024)

In a Phase IIa study in patients with metabolic dysfunction-associated steatotic liver disease, retatrutide was associated with a significant reduction in liver fat content, measured by MRI-PDFF, in a high proportion of participants. The glucagon component is cited as a possible driver of this effect. These are early data, still to be confirmed in later phases.

Phase III — TRIUMPH programme

The large-scale Phase III TRIUMPH programme is evaluating retatrutide in obesity, in type 2 diabetes and in related metabolic conditions, including studies with long-term and cardiovascular endpoints. Until this programme is completed and regulatory evaluation takes place, retatrutide remains experimental and is not approved for clinical use.

Note: The information on clinical studies is provided as scientific reference and is based on published or publicly announced results. It does not constitute medical advice, a recommendation for use or a claim about the result of the product offered by Peptology.

Documented clinical results of retatrutide

• One of the largest weight reductions in the incretin category — mean reduction ~24.2% with 12 mg at week 48 in Phase II (NEJM, 2023)
• Weight reduction ≥ 5% in all participants at 8 mg and 12 mg in the Phase II obesity study
• Dose-dependent improvements in HbA1c and glycaemic control in Phase II in type 2 diabetes (Lancet, 2023)
• Significant reduction in liver fat in Phase IIa in MASLD/NASH (Nature Medicine, 2024)
• Improvements in cardiometabolic markers — waist circumference, blood pressure, insulin and lipid profile
• Return to normoglycaemia in a high proportion of participants with prediabetes in Phase II
• Triple receptor mechanism — the only molecule in the catalogue that simultaneously activates the GLP-1, GIP and glucagon receptors

All results mentioned relate to published clinical studies of retatrutide and should not be interpreted as a promise of results, instructions for use or a claim about the action of the research-grade product offered by Peptology.

Related peptides in the Peptology catalogue

Researchers working with retatrutide often also examine the peptides below from the metabolic peptide / GLP-1 agonist and cellular energy molecule categories. Each of them has a purity certificate of over 99%:

See the whole catalogue: Peptides for weight loss — GLP-1 agonists · Tirzepatide · All peptides · Blog

How does retatrutide differ from Tirzepatide and Semaglutide?

The main difference is the number of receptors. Semaglutide acts only on the GLP-1 receptor; Tirzepatide — on the GLP-1 and GIP receptors; while retatrutide adds a third — the glucagon receptor. In the literature, the glucagon component refers to the additional activation of the glucagon receptor (GCGR), which makes retatrutide a subject of distinct scientific interest.

Can retatrutide be combined with other peptides?

Combinations between metabolic peptides or with cellular energy molecules (e.g. SS-31 or NAD+ ) are a subject of scientific interest because of complementary mechanisms, but have not been systematically studied under controlled clinical conditions. They remain a subject of research and not a recommendation for use.

Molecule identity

References

1. Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514–526.
2. Rosenstock J et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402:529–544.
3. Sanyal AJ et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037–2048.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–216.
5. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989–1002.

Buy Retatrutide in Cyprus – price

You can buy Retatrutide in Cyprus online from Peptology. Prices by strength:

• 5mg: €59.00
• 10mg: €99.00
• 15mg: €125.00
• 30mg: €159.00

Orders placed by 15:00 on working days ship the same day and are delivered in 5–7 working days with BOX NOW. Shipping costs €2 and is free from €50; you pay on delivery – by card through the BOX NOW payment link, before you open the locker.

Retatrutide 5/10/15/30 mg: which strength

Retatrutide is available in: 5/10/15/30 mg.

Available strengths: 5 mg, 10 mg, 15 mg and 30 mg

Retatrutide is available in four lyophilised forms, covering different scales of research work — from individual in vitro series and validation experiments to longer protocols with higher peptide consumption.

All four forms — 5 mg, 10 mg, 15 mg and 30 mg — have the same purity > 99% and an identical laboratory certificate for the corresponding batch. The choice of size depends on the scale of the protocol and not on the concentration of the active substance.

Research protocols

Unlike peptides with a short half-life, retatrutide has a long half-life (~6 days) and in the clinical programmes is administered once a week, with gradual escalation of the dose to limit gastrointestinal effects. The typical titration scheme in the studies follows steps of 4 weeks:

• Phase I (dose escalation): starting with a low dose and gradual increase within a research protocol
• Phase II (obesity): weekly doses of 1, 4, 8 or 12 mg SC, reached by escalation every 4 weeks
• Typical titration scheme: 2 mg weekly (wk 1–4) → 4 mg (wk 5–8) → 8 mg (wk 9–12) → 12 mg maintenance dose (wk 13+)
• Phase II (type 2 diabetes / MASLD): weekly SC doses according to the clinical protocol

Similar to other GLP-1 peptides, such as Semaglutide and Tirzepatide, retatrutide requires slow titration for good tolerability — in the clinical studies the dose is increased gradually rather than starting directly at the target level. These regimens are part of controlled clinical trials and are not a recommendation for self-administration.

Storage and reconstitution

Retatrutide is supplied as a lyophilised (freeze-dried) powder in a vial. In lyophilised form the peptide is stable both in the refrigerator and at room temperature, protected from light and moisture. After reconstitution, stability depends on the solvent used, with Peptide Matrix Water™ significantly extending the shelf life of the peptide.

• Before reconstitution: store in the original packaging, protected from light and moisture; for long-term storage a refrigerator (2–8 °C) or freezer is recommended. Shelf life: up to 24 months with correct storage.
• After reconstitution with Peptide Matrix Water™: stability in the refrigerator at 2–8 °C for up to 60 days under suitable laboratory conditions — the stabilising composition extends the shelf life of the peptide compared with common solvents.
• After reconstitution with bacteriostatic or sterile water: stability in the refrigerator at 2–8 °C for up to 28 days under suitable laboratory conditions. Do not freeze the reconstituted solution again.
• Reconstitution: in a laboratory environment, Peptide Matrix Water™, bacteriostatic or sterile water for injection is usually used, depending on the specific research protocol.
• Concentration: determined according to the vial strength (5, 10, 15 or 30 mg) and the aims of the study; it can be calculated with our peptide reconstitution calculator.
• Homogenisation: the solvent is added slowly along the wall of the vial, without vigorous agitation — peptide bonds are sensitive to mechanical stress.

Tip for laboratory work: When ordering, you can add Peptide Matrix Water™ to the basket — a stabilising solution designed for work with reconstituted research peptides.

How is retatrutide stored?

The vial with the lyophilised peptide is stored protected from light and moisture; for long-term storage a refrigerator or freezer is recommended. After reconstitution, stability depends on the solvent: with Peptide Matrix Water™ — up to 60 days in the refrigerator at 2–8 °C; with bacteriostatic or sterile water — up to 28 days. In every case, avoid re-freezing.

Purity and certificate of analysis

99%+ purity, HPLC/MS certificate for every batch.

Retatrutide - 5mg - Batch - 0226 - Purity & Endotoxins

Retatrutide - 10mg - Batch - 0226 - Purity & Endotoxins

Retatrutide - 15mg - Batch - 0226 - Purity & Endotoxins

Retatrutide - 30mg - Batch - 0226 - Purity & Endotoxins

Shipping and payment

Orders placed by 15:00 on working days ship the same day and are delivered in 5–7 working days with BOX NOW. Shipping costs €2 and is free from €50; you pay on delivery – by card through the BOX NOW payment link, before you open the locker.

Frequently asked questions about Retatrutide

Where can I buy Retatrutide in Cyprus and what does it cost?

In Cyprus you can buy Retatrutide online from Peptology, from €59.00 (5mg: €59.00, 10mg: €99.00, 15mg: €125.00, 30mg: €159.00). Delivery in 5–7 working days with BOX NOW, free from €50; you pay on delivery – by card through the BOX NOW payment link, before you open the locker.

What is Retatrutide (Reta)?

Retatrutide activates three receptors simultaneously. In the literature, the GLP-1 component is linked with activation of the GLP-1 receptor in central pathways and glucose-dependent insulin secretion; the GIP component — with improved insulin sensitivity; and the glucagon component (GCGR) — with activation of the glucagon receptor (GCGR). The combination of these three pathways differs fundamentally from incretin peptides that act on one or two receptors. These results come from controlled laboratory and clinical studies.

In what form is Retatrutide available?

As a lyophilised powder in a glass vial (5/10/15/30 mg). It is reconstituted in the laboratory with Peptide Matrix Water™ or bacteriostatic water; you can work out the concentration (mg/mL) with the <a href="/page/peptide-calculator">reconstitution calculator</a>.

How long does delivery take and how do I pay?

Orders placed by 15:00 on working days ship the same day and are delivered in 5–7 working days with BOX NOW. Shipping costs €2 and is free from €50; you pay on delivery – by card through the BOX NOW payment link, before you open the locker.